Mustang Bio, Inc. (MBIO) vs Nexalin Technology, Inc. (NXL)
A side-by-side comparison of Mustang Bio, Inc. and Nexalin Technology, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
MBIO
Mustang Bio, Inc.
$0.46HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT
NXL
Nexalin Technology, Inc.
$4.81HealthcareDelayed quote: Oct 6, 2026, 2:47 PM EDT
Total return — MBIO vs NXL
growth of $100 · dividends reinvested · last 4yMBIO -99.9% (-82.0%/yr)NXL -92.0% (-46.7%/yr)NXL compounded faster over this window
Log scale — wide-divergence pair
MBIO NXL
MBIO vs NXL: by the numbers
- •NXL is the larger company ($4M vs $3M market cap).
- •Both run net losses; MBIO's is the smaller (0.00% vs -4139.38% net margin).
Metrics side by side
Valuation
| Metric | MBIO | NXL |
|---|---|---|
| P/S ratio | N/A | 16.25 |
| P/B ratio | 0.46 | 2.32 |
Profitability
| Metric | MBIO | NXL |
|---|---|---|
| Gross margin | 0.00% | 79.65% |
| Operating margin | 0.00% | -2781.69% |
| Net margin | 0.00% | -4139.38% |
| ROE | -40.20% | -591.60% |
| ROIC | -45.77% | -600.62% |
Growth (annualized)
| Metric | MBIO | NXL |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 10.22% |
| Total return CAGR (5Y) | -80.80% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.